Alberta residents with neovascular (wet) age-related macular degeneration (AMD), the leading cause of vision loss over the age of 50, have received a dose of good news with the decision by Alberta Health and Wellness to reimburse the innovative treatment Lucentis* (ranibizumab) on the Alberta Blue Cross insurance plan.